Pharmaceuticals

Peptide Antibiotics Global Forecast: Market to Scale Up to $9.04 Billion by 2030 at 9.3% CAGR

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the peptide antibiotics market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Peptide Antibiotics Market?

The peptide antibiotics market has experienced significant growth in recent years. It is anticipated to increase from $5.77 billion in 2025 to $6.32 billion in 2026, showing a compound annual growth rate (CAGR) of 9.6%. This historical growth can be linked to factors such as the rise of bacterial strains resistant to antibiotics, an increase in hospital-acquired infection rates, developments in peptide synthesis technologies, expanding clinical research into infectious diseases, and government funding directed towards antibiotic research and development.

The peptide antibiotics market size is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $9.04 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This forecasted growth is largely driven by factors such as the increasing incidence of multi-drug resistant infections, the expanding global healthcare infrastructure, innovations in peptide delivery technologies, a rise in partnerships with CDMOs, and the growing embrace of precision medicine strategies. Key trends expected during this period involve a heightened demand for solutions addressing multi-drug resistant (MDR) infections, the broader application of peptide antibiotics in combating hospital-acquired infections, an increase in contract manufacturing and CDMO collaborations, the greater adoption of personalized and targeted antibiotic treatments, and an emphasis on developing peptide antibiotics that offer reduced toxicity and fewer side effects.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7780&type=smp

What Drivers Are Supporting Technological Adoption In The Peptide Antibiotics Market?

The growing incidence of diverse infectious diseases is projected to drive the expansion of the Peptide Antibiotics Market. These illnesses are caused by harmful microorganisms such as bacteria, fungi, and parasites. Key factors contributing to the increase in infectious diseases include rapid urbanization, climate change, and a higher risk of disease emergence, all of which have boosted the demand for peptide antibiotics. Peptide antibiotics function by physically disrupting cell membranes, which underlies their antibacterial action. For example, in May 2024, the World Health Organization, a Switzerland-based intergovernmental body, reported that dengue cases in the America region had already surpassed seven million by April 2024, a figure significantly higher than the 4.6 million cases recorded throughout 2023. Consequently, the rising occurrence of infectious diseases is fueling the growth of the Peptide Antibiotics Market. The rising incidence of chronic diseases is anticipated to propel the Peptide Antibiotics Market. Chronic diseases are conditions that persist for a year or longer, necessitate ongoing medical attention, and restrict daily activities. The increasing prevalence of chronic diseases is attributed to factors like heightened tobacco use, poor nutrition, physical inactivity, excessive alcohol consumption, and others. Peptide antibiotics are employed in treating chronic diseases through targeted drug administration to the affected area. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, over 35 million new cancer cases would emerge, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of chronic conditions is stimulating the growth of the Peptide Antibiotics Market.

Which Segments Are Contributing To The Growth Of The Peptide Antibiotics Market?

The peptide antibiotics market covered in this report is segmented –

1) By Type: Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomal Synthesized Peptide Antibiotics

2) By Drugs: Daptomycin, Dalbavancin, Telavancin, Other Drugs

3) By Disease Outlook: Skin Infection, HABP Or VABP, Blood Stream Infection, Other Diseases

4) By Distribution Channel: Hospitals, Homecare, Specialty Clinics, Other Distribution Channels

Subsegments:

1) By Ribosomal Synthesized Peptide Antibiotics: Aminoglycosides, Macrolides, Tetracyclines, Lincosamides

2) By Non-Ribosomal Synthesized Peptide Antibiotics: Bacitracins, Vancomycin, Polymyxins, Cyclic Lipopeptides

How Are Emerging Trends Affecting The Progression Of The Peptide Antibiotics Market?

Major companies operating in the peptide antibiotics market are actively introducing generic versions to present an affordable alternative to patients. These generic versions of peptide antibiotics offer cost-effective, off-patent alternatives to brand-name peptide-based antibiotics, which are employed in treating diverse bacterial infections. For example, in July 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, broadened its product portfolio with the release of a generic version of Daptomycin for Injection. Daptomycin for Injection is categorized as a peptide antibiotic, specifically a cyclic lipopeptide antibiotic that is synthesized by a non-ribosomal machinery. This generic version is accessible in both 350 mg and 500 mg strengths and is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in adult patients and pediatric patients aged 1 to 17 years.

Who Are The Primary Competitors In The Global Peptide Antibiotics Market?

Major companies operating in the peptide antibiotics market are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, Allecra Therapeutics GmbH, Basilea Pharmaceutica Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Peptide Antibiotics Market?

North America was the largest region in the peptide antibiotics market in 2025. The regions covered in the peptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Peptide Antibiotics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7780&type=smp

Browse Through More Reports Similar to the Global Peptide Antibiotics Market 2026, By The Business Research Company

Peptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795